BioMarin EVP sells 3,281 shares at $53.85

BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold shares in an open-market transaction.

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold shares in an open-market transaction. On May 7, 2026, he sold 3,281 shares of common stock at $53.85 per share. After this sale, he directly owns 51,818 shares of BioMarin common stock.

Insights

Equity market analyst

Executive’s sale is relatively small versus remaining holdings.

Executive Vice President and Chief R&D Officer Gregory R. Friberg executed an open-market sale of 3,281 shares of BioMarin common stock at $53.85 per share on May 7, 2026.

Following the sale, Friberg continues to hold 51,818 shares directly. The transaction reduces his position only modestly, which often reflects routine liquidity or portfolio management rather than a major change in outlook, based solely on the data provided here.

Insider Trade Summary

Net Seller: 3,281 shares

Net Sell 1 txn

Insider Friberg Gregory R

Role EVP, Chief R&D Officer

Sold 3,281 shs ($177K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,281	$53.85	$177K

Holdings After Transaction: Common Stock — 51,818 shares (Direct)

Key Figures

Shares sold: 3,281 shares Sale price: $53.85 per share Shares held after sale: 51,818 shares

3 metrics

Shares sold 3,281 shares Open-market sale of BioMarin common stock

Sale price $53.85 per share Price for 3,281 shares sold on May 7, 2026

Shares held after sale 51,818 shares Direct holdings following the reported transaction

Key Terms

open-market sale, Common Stock, Form 4, transaction code "S"

4 terms

open-market sale financial

"transaction_action: "open-market sale" for the common stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" for the non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) describing BioMarin insider activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "S" financial

"transaction_code: "S" indicating a sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioMarin (BMRN) executive Gregory R. Friberg do in this Form 4?

Gregory R. Friberg, BioMarin’s EVP and Chief R&D Officer, reported an open-market sale of common stock. He sold 3,281 shares at $53.85 per share, documenting the transaction and his updated holdings with the SEC on this Form 4.

How many BioMarin (BMRN) shares did Gregory R. Friberg sell and at what price?

Gregory R. Friberg sold 3,281 shares of BioMarin common stock. The reported sale price was $53.85 per share in an open-market transaction, providing a clear record of both volume and execution price for investors reviewing insider activity.

What are Gregory R. Friberg’s BioMarin (BMRN) holdings after this transaction?

After the reported sale, Gregory R. Friberg directly holds 51,818 shares of BioMarin common stock. This figure reflects his remaining ownership position following the 3,281-share open-market sale disclosed in the Form 4 filing.

What type of transaction did BioMarin (BMRN) report for Gregory R. Friberg?

The filing shows an open-market sale of common stock, coded as an “S” transaction. This indicates Friberg disposed of 3,281 shares by selling them on the market at a reported price of $53.85 per share.

Does the BioMarin (BMRN) Form 4 show any option exercises or derivative positions?

The data provided shows no derivative transactions or option exercises for this Form 4. The derivative summary is empty, and the only reported activity is a non-derivative open-market sale of 3,281 shares of BioMarin common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 05:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friberg Gregory R

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		S		3,281	D	$53.85	51,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)